{
    "clinical_study": {
        "@rank": "109097", 
        "arm_group": [
            {
                "arm_group_label": "Only radiation therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
            }, 
            {
                "arm_group_label": "Radiation therapy plus DC-CIK cellular therapy", 
                "arm_group_type": "Experimental", 
                "description": "Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.\nDC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
            }
        ], 
        "brief_summary": {
            "textblock": "Cytokine-induced killer (CIK) cells show cytolytic activity against tumor. Radiation therapy\n      uses high-energy x-rays to damage tumor cells. Combining Radiation therapy with adoptive\n      cellular therapy after surgery may be more effective than uses radiation therapy alone in\n      treating esophageal cancer."
        }, 
        "brief_title": "Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer", 
        "condition": "Esophageal Cancer", 
        "condition_browse": {
            "mesh_term": "Esophageal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  cytologically or histologically confirmed esophageal carcinoma\n\n          -  Tumor extension beyond muscularis propria and/or nodal involvement without evidence\n             of M1 disease\n\n          -  Prior en bloc resection, with curative intent, of all known tumor\n\n          -  No metastatic disease\n\n          -  Age: > 18\n\n          -  Karnofsky performance status \u2265 70\n\n          -  At least 3 weeks since prior surgery\n\n          -  Normal functions of heart, lung, liver, kidney and bone marrow\n\n          -  Blood exams qualified for chemotherapy, which included hemoglobulin \u22659 g/dl,\n             neutrophil \u22651.5\u00d7109/L and platelet (PLT) \u2265100\u00d7109/L, creatinine \u22641.5 UNL\n\n          -  All patients must be evaluated by a radiation oncologist prior to enrollment to\n             ensure patient is appropriate for radiotherapy\n\n          -  Informed consent signed\n\n        Exclusion Criteria:\n\n          -  Patients with metastatic disease.\n\n          -  Patients who are pregnant or nursing.\n\n          -  Patients with poor bone marrow, liver and kidney functions, which would make\n             radiation therapy intolerable\n\n          -  Patients with contraindication for irradiation: complete obstruction of esophagus,\n             deep esophageal ulcer, fistula to mediastinum, or haematemesis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691664", 
            "org_study_id": "JR-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Only radiation therapy", 
                "description": "Patients only radiation therapy after surgery", 
                "intervention_name": "Only radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Radiation therapy plus DC-CIK cellular therapy", 
                "description": "Patients receive radiation therapy plus DC-CIK cellular therapy after surgery", 
                "intervention_name": "Radiation therapy plus DC-CIK cellular therapy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Esophageal Cancer", 
            "DC-CIK", 
            "immunotherapy", 
            "cellular therapy", 
            "radiation therapy"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "location": {
            "contact": {
                "last_name": "Jun Ren, MD, PhD", 
                "phone": "86-10-63926317"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100038"
                }, 
                "name": "Beijing Shijitan Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "measure": "Immunological assessment", 
            "safety_issue": "No", 
            "time_frame": "Initial assessment, months 1,3,6and 12"
        }, 
        "overall_contact": {
            "email": "renjun9688@yahoo.com", 
            "last_name": "Jun Ren, MD,PhD", 
            "phone": "86-10-63926317"
        }, 
        "overall_official": {
            "affiliation": "Capital Medical University Cancer Center", 
            "last_name": "Jun Ren, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Beijing Municipal Bureau of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease free survival", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691664"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Capital Medical University", 
            "investigator_full_name": "Jun Ren MD, PhD", 
            "investigator_title": "Director, Capital Medical University Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "quality of life", 
            "safety_issue": "No", 
            "time_frame": "Initial assessment \u2192  months 1,3,6 and 12"
        }, 
        "source": "Capital Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Capital Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}